Loading...

COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution

Published
06 Aug 24
Updated
04 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
46.4%
7D
7.0%

Author's Valuation

US$338.297.8% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 04 Nov 25

Fair value Increased 1.50%

Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.

Shared on 04 Sep 25

With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.

Shared on 07 May 25

Fair value Increased 9.57%

Shared on 30 Apr 25

Fair value Increased 0.84%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Increased 0.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Increased 3.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.55%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.